Scholar Rock (SRRK) Expected to Post Earnings on Thursday

Scholar Rock (NASDAQ:SRRK) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.8405) per share and revenue of $3.3330 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the prior year, the firm posted ($0.67) earnings per share. On average, analysts expect Scholar Rock to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Scholar Rock Stock Performance

SRRK stock opened at $47.79 on Wednesday. Scholar Rock has a one year low of $27.07 and a one year high of $58.49. The firm has a market cap of $5.73 billion, a price-to-earnings ratio of -13.31 and a beta of 0.69. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64. The firm has a 50-day simple moving average of $49.99 and a two-hundred day simple moving average of $47.75.

Wall Street Analysts Forecast Growth

SRRK has been the subject of several recent analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Canaccord Genuity Group began coverage on Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 price target on the stock. HC Wainwright increased their price objective on Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a report on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research report on Friday, July 17th. Finally, Wedbush reissued an “outperform” rating and issued a $58.00 price objective on shares of Scholar Rock in a research report on Tuesday, July 21st. Four research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and an average target price of $56.21.

Insider Buying and Selling at Scholar Rock

In other news, Director Jeffrey S. Flier sold 3,053 shares of Scholar Rock stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $164,495.64. Following the completion of the sale, the director directly owned 27,856 shares in the company, valued at approximately $1,500,881.28. The trade was a 9.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Gilman sold 2,544 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total value of $137,045.28. Following the completion of the transaction, the director directly owned 59,511 shares in the company, valued at approximately $3,205,857.57. The trade was a 4.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 17,149 shares of company stock worth $923,108 in the last three months. 10.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Scholar Rock during the fourth quarter worth about $30,000. Summit Securities Group LLC acquired a new position in Scholar Rock in the 4th quarter worth approximately $31,000. Strs Ohio purchased a new position in Scholar Rock during the 1st quarter worth approximately $77,000. US Bancorp DE raised its position in Scholar Rock by 81.6% during the 3rd quarter. US Bancorp DE now owns 2,822 shares of the company’s stock worth $105,000 after buying an additional 1,268 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in Scholar Rock during the 4th quarter valued at approximately $114,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).